Clinical Trial

A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts. This study will be held in approximately 5-8 study sites in United States
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-12-20; most recent amendment 2026-02-26.
Trial Details
NCT Number NCT06753331
Lead Sponsor Sumitomo Pharma America, Inc.
Conditions Parkinson's Disease
Enrollment 25 participants
Start Date 2024-12-18
Primary Completion 2030-12-15 (estimated)
Study Completion 2030-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-02